Oxygen Biotherapeutics Announces It Will Present at the 15th Annual BIO CEO & Investor Conference on February 11

BIO CEO & Investor Conference 2013

MORRISVILLE, N.C.--()--Oxygen Biotherapeutics, Inc. ("Oxygen") (NASDAQ:OXBT) announced today the Company will be presenting at the 15th Annual BIO CEO & Investor Conference to be held at the Waldorf Astoria Hotel in New York City, February 11-12. Michael Jebsen, President and Chief Financial Officer of Oxygen, will present a corporate overview and update on Monday, February 11 at 9 am EST. The presentation will be webcast live and can be accessed on the company’s web site or by clicking on the following link http://www.veracast.com/webcasts/bio/ceoinvestor2013/12102288.cfm. A replay will be made available for a limited time online on the company’s web site.

The conference, organized by the Biotechnology Industry Organization, is designed to offer participating companies networking opportunities to build awareness, establish partnerships and to attract investors. For more information on the conference, click here.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is developing medical products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte® that is currently in clinical and preclinical studies for intravenous delivery for indications such as traumatic brain injury, decompression sickness and stroke. The company has also developed PFC-based creams and gels for topical delivery to the skin potentially for wound care and dermatologic conditions.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the company's judgment as of the date of this release. The forward-looking statements are subject to a number of risks and uncertainties including matters beyond the company's control that could lead to delays in new product introductions and customer acceptance of these new products, and other risks and uncertainties as described in our filings with the Securities and Exchange Commission, including in the current Form 10-Q filed on December 14, 2012, and our annual report on Form 10-K filed on July 24, 2012, as well as other filings with the SEC. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contacts

Oxygen Biotherapeutics, Inc.
Ellen Corliss, 919-855-2112
Senior Vice President,
Corporate Communications & Investor Relations

Release Summary

Don't miss a great opportunity to hear the Oxygen Bio corporate story directly from the President and CFO at the BIO CEO & Investor Conference on Feb. 11 at 9 am

Sharing

Contacts

Oxygen Biotherapeutics, Inc.
Ellen Corliss, 919-855-2112
Senior Vice President,
Corporate Communications & Investor Relations